Aptahem’s CEO interviewed during the Biotechgate conference
Mikael Lindstam, CEO at Aptahem, was interviewed during the Biotechgate digital partnering conference. In the video he describes the development process with the company’s lead candidate Apta-1, from discovery, through manufacturing and preclinical studies up to clinical phase. The interview also explains why Apta-1 is thought to be a potential drug candidate for sepsis.Watch the interview with Aptahem's CEO Mikael Lindstam by following the link below: https://youtu.be/LthryhUCxjE For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@